Advertisement

Topics

J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far

05:41 EST 11 Jan 2019 | Pharmafile

It’s only the second week of the New Year, and Johnson & Johnson has announced plans to hike the prices of more than 20 of its products, many of which are already among its best-selling.

The hiked medicines include psoriasis drug Stelara, blood thinner Xarelto and prostate cancer therapy Zytiga, with the majority of increases reaching between 6% and 7%.

Despite the move, J&J spokesman Ernie Knewitz gave assurances that the company has no plans for any further price increases this year.

read more

Original Article: J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far

NEXT ARTICLE

More From BioPortfolio on "J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...